Molecular Predictors of Survival after Adjuvant Chemotherapy for Colon Cancer
Toshiaki Watanabe, M.D., Tsung-Teh Wu, M.D., Ph.D., Paul J. Catalano, Sc.D., Takashi Ueki, M.D., Ph.D., Robert Satriano, Daniel G. Haller, M.D., Al B. Benson, M.D., and Stanley R. Hamilton, M.D.
Background Adjuvant chemotherapy improves survival among patientswith stage III colon cancer, but no reliable molecular predictorsof outcome have been identified.
Methods We evaluated loss of chromosomal material (also calledloss of heterozygosity or allelic loss) from chromosomes 18q,17p, and 8p; cellular levels of p53 and p21WAF1/CIP1 proteins;and microsatellite instability as molecular markers. We analyzedtumor tissue from 460 patients with stage III and high-riskstage II colon cancer who had been treated with various combinationsof adjuvant fluorouracil, leucovorin, and levamisole to determinethe ability of these markers to predict survival.
Results Loss of heterozygosity at 18q was present in 155 of319 cancers (49 percent). High levels of microsatellite instabilitywere found in 62 of 298 tumors (21 percent), and 38 of these62 tumors (61 percent) had a mutation of the gene for the typeII receptor for transforming growth factor 1 (TGF-1). Amongpatients with microsatellite-stable stage III cancer, five-yearoverall survival after fluorouracil-based chemotherapy was 74percent in those whose cancer retained 18q alleles and 50 percentin those with loss of 18q alleles (relative risk of death withloss at 18q, 2.75; 95 percent confidence interval, 1.34 to 5.65;P=0.006). The five-year survival rate among patients whose cancerhad high levels of microsatellite instability was 74 percentin the presence of a mutated gene for the type II receptor forTGF-1 and 46 percent if the tumor did not have this mutation(relative risk of death, 2.90; 95 percent confidence interval,1.14 to 7.35; P=0.03).
Conclusions Retention of 18q alleles in microsatellite-stablecancers and mutation of the gene for the type II receptor forTGF-1 in cancers with high levels of microsatellite instabilitypoint to a favorable outcome after adjuvant chemotherapy withfluorouracil-based regimens for stage III colon cancer.
Source Information
From the Division of GastrointestinalLiver Pathology, Department of Pathology (T.W., T.-T.W., T.U., R.S., S.R.H.), and the Oncology Center (S.R.H.), Johns Hopkins University School of Medicine, Baltimore; the Department of Biostatistical Science, DanaFarber Cancer Institute, Boston (P.J.C.); the HematologyOncology Department, University of Pennsylvania Cancer Center, Philadelphia (D.G.H.); the Division of HematologyOncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago (A.B.B.); the Division of Pathology and Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston (S.R.H.); and the Eastern Cooperative Oncology Group, Brookline, Mass. (P.J.C., D.G.H., A.B.B., S.R.H.).
Address reprint requests to Dr. Hamilton at the Division of Pathology and Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 85, G1.3754, Houston, TX 77030.
Yang, L., Moses, H. L.
(2008). Transforming Growth Factor {beta}: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?. Cancer Res.
68: 9107-9111
[Abstract][Full Text]
Zell, J. A., Honda, J., Ziogas, A., Anton-Culver, H.
(2008). Survival After Colorectal Cancer Diagnosis Is Associated with Colorectal Cancer Family History. Cancer Epidemiol. Biomarkers Prev.
17: 3134-3140
[Abstract][Full Text]
Pal, T., Permuth-Wey, J., Kumar, A., Sellers, T. A.
(2008). Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology. Clin. Cancer Res.
14: 6847-6854
[Abstract][Full Text]
Lurje, G., Zhang, W., Schultheis, A. M., Yang, D., Groshen, S., Hendifar, A. E., Husain, H., Gordon, M. A., Nagashima, F., Chang, H. M., Lenz, H.-J.
(2008). Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol
19: 1734-1741
[Abstract][Full Text]
Lefevre, J. H., Rondelli, F., Mourra, N., Bennis, M., Tiret, E., Parc, R., Parc, Y.
(2008). Lumboaortic and Iliac Lymphadenectomy for Lymph Node Recurrence of Colorectal Cancer: Prognostic Value of the MSI Phenotype. Ann. Surg. Oncol.
15: 2433-2438
[Abstract][Full Text]
John, T., Black, M. A., Toro, T. T., Leader, D., Gedye, C. A., Davis, I. D., Guilford, P. J., Cebon, J. S.
(2008). Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma. Clin. Cancer Res.
14: 5173-5180
[Abstract][Full Text]
Jiang, Y., Casey, G., Lavery, I. C., Zhang, Y., Talantov, D., Martin-McGreevy, M., Skacel, M., Manilich, E., Mazumder, A., Atkins, D., Delaney, C. P., Wang, Y.
(2008). Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon Cancer. J. Mol. Diagn.
10: 346-354
[Abstract][Full Text]
Pasche, B.
(2008). Familial Colorectal Cancer: A Genetics Treasure Trove for Medical Discovery. JAMA
299: 2564-2565
[Full Text]
Watanabe, T., Yamamoto, Y., Yamada, H., Hayama, T., Aoyagi, Y., Nakamura, K., Shibuya, H., Kobunai, T.
(2008). Survival in Microsatellite-Unstable Colorectal Cancer. Clin. Cancer Res.
14: 2516-2516
[Full Text]
Ogino, S., Goel, A.
(2008). Molecular Classification and Correlates in Colorectal Cancer. J. Mol. Diagn.
10: 13-27
[Abstract][Full Text]
Benson, A. B. III
(2007). New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease. Clin. Cancer Res.
13: 6913s-6920s
[Abstract][Full Text]
Malesci, A., Laghi, L., Bianchi, P., Delconte, G., Randolph, A., Torri, V., Carnaghi, C., Doci, R., Rosati, R., Montorsi, M., Roncalli, M., Gennari, L., Santoro, A.
(2007). Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer. Clin. Cancer Res.
13: 3831-3839
[Abstract][Full Text]
O'Dwyer, P. J., Eckhardt, S. G., Haller, D. G., Tepper, J., Ahnen, D., Hamilton, S., Benson, A. B. III, Rothenberg, M., Petrelli, N., Lenz, H.-J., Diasio, R., DuBois, R., Sargent, D., Sloan, J., Johnson, C. D., Comis, R. L., O'Connell, M. J.
(2007). Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. JCO
25: 2313-2321
[Abstract][Full Text]
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., Mayer, R. J.
(2007). Adjuvant Treatment of Colorectal Cancer. CA Cancer J Clin
57: 168-185
[Abstract][Full Text]
Gasser, M., Gerstlauer, C., Grimm, M., Bueter, M., Lebedeva, T., Lutz, J., Maeder, U., Ribas, C., Ribas, C., Nichiporuk, E., Thalheimer, A., Heemann, U., Thiede, A., Meyer, D., Waaga-Gasser, A. M.
(2007). Comparative Analysis of Predictive Biomarkers for Therapeutical Strategies in Colorectal Cancer. Ann. Surg. Oncol.
14: 1272-1284
[Abstract][Full Text]
Kim, G. P., Colangelo, L. H., Wieand, H. S., Paik, S., Kirsch, I. R., Wolmark, N., Allegra, C. J.
(2007). Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. JCO
25: 767-772
[Abstract][Full Text]
Wong, J J L, Hawkins, N J, Ward, R L
(2007). Colorectal cancer: a model for epigenetic tumorigenesis. Gut
56: 140-148
[Full Text]
Carethers, J M
(2006). Authors' reply.. Gut
55: 1819-1819
[Full Text]
Bamias, A, Yu, Z, Weinberger, P., Markakis, S, Kowalski, D, Camp, R., Rimm, D., Dimopoulos, M., Psyrri, A
(2006). Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with {beta}-catenin levels and outcome in patients with epithelial ovarian cancer. Ann Oncol
17: 1797-1802
[Abstract][Full Text]
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., Bast, R. C. Jr
(2006). ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. JCO
24: 5313-5327
[Abstract][Full Text]
Iacopetta, B, Watanabe, T
(2006). Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.. Gut
55: 1671-1672
[Full Text]
Watanabe, T., Kobunai, T., Toda, E., Yamamoto, Y., Kanazawa, T., Kazama, Y., Tanaka, J., Tanaka, T., Konishi, T., Okayama, Y., Sugimoto, Y., Oka, T., Sasaki, S., Muto, T., Nagawa, H.
(2006). Distal Colorectal Cancers with Microsatellite Instability (MSI) Display Distinct Gene Expression Profiles that Are Different from Proximal MSI Cancers. Cancer Res.
66: 9804-9808
[Abstract][Full Text]
Benson, A. B. III
(2006). New Approaches to the Adjuvant Therapy of Colon Cancer. The Oncologist
11: 973-980
[Abstract][Full Text]
Ji, H., Kumm, J., Zhang, M., Farnam, K., Salari, K., Faham, M., Ford, J. M., Davis, R. W.
(2006). Molecular Inversion Probe Analysis of Gene Copy Alterations Reveals Distinct Categories of Colorectal Carcinoma. Cancer Res.
66: 7910-7919
[Abstract][Full Text]
Iacopetta, B, Li, W Q, Grieu, F, Ruszkiewicz, A, Kawakami, K
(2006). BRAF mutation and gene methylation frequencies of colorectal tumours with microsatellite instability increase markedly with patient age.. Gut
55: 1213-1213
[Full Text]
Biswas, S., Criswell, T. L., Wang, S. E., Arteaga, C. L.
(2006). Inhibition of Transforming Growth Factor-{beta} Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy.. Clin. Cancer Res.
12: 4142-4146
[Full Text]
Watanabe, T., Kanazawa, T., Kazama, Y., Tanaka, J., Tanaka, T., Ishihara, S., Nagawa, H., Benatti, P., Ponz de Leon, M., Gafa, R., Lanza, G., Barana, D., Oliani, C.
(2006). Adjuvant chemotherapy in colorectal cancer patients with microsatellite instability.. Clin. Cancer Res.
12: 3866-3867
[Full Text]
Andre, T., Sargent, D., Tabernero, J., O'Connell, M., Buyse, M., Sobrero, A., Misset, J.-L., Boni, C., de Gramont, A.
(2006). Current Issues in Adjuvant Treatment of Stage II Colon Cancer. Ann. Surg. Oncol.
13: 887-898
[Abstract][Full Text]
Melloni, G., Doglioni, C., Bandiera, A., Carretta, A., Ciriaco, P., Arrigoni, G., Zannini, P.
(2006). Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma. Ann. Thorac. Surg.
81: 2008-2013
[Abstract][Full Text]
Jover, R, Zapater, P, Castells, A, Llor, X, Andreu, M, Cubiella, J, Pinol, V, Xicola, R M, Bujanda, L, Rene, J M, Clofent, J, Bessa, X, Morillas, J D, Nicolas-Perez, D, Paya, A, Alenda, C, for the Gastrointestinal Oncology Group of the Spa,
(2006). Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut
55: 848-855
[Abstract][Full Text]
Goldberg, R. M., Niedzwiecki, D., Bertagnolli, M., Blackstock, A. W., Tepper, J. E., Mayer, R. J.
(2006). Cancer and leukemia group B gastrointestinal cancer committee.. Clin. Cancer Res.
12: 3589s-3595s
[Abstract][Full Text]
Lanza, G., Gafa, R., Santini, A., Maestri, I., Guerzoni, L., Cavazzini, L.
(2006). Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients. JCO
24: 2359-2367
[Abstract][Full Text]
Lu, S.-L., Herrington, H., Reh, D., Weber, S., Bornstein, S., Wang, D., Li, A. G., Tang, C.-F., Siddiqui, Y., Nord, J., Andersen, P., Corless, C. L., Wang, X.-J.
(2006). Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma.. Genes Dev.
20: 1331-1342
[Abstract][Full Text]
Paroder, V., Spencer, S. R., Paroder, M., Arango, D., Schwartz, S. Jr., Mariadason, J. M., Augenlicht, L. H., Eskandari, S., Carrasco, N.
(2006). Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: Molecular characterization of SMCT. Proc. Natl. Acad. Sci. USA
103: 7270-7275
[Abstract][Full Text]
Park, Y.-A., Lee, K. Y., Kim, N. K., Baik, S. H., Sohn, S. K., Cho, C. W.
(2006). Prognostic Effect of Perioperative Change of Serum Carcinoembryonic Antigen Level: A Useful Tool for Detection of Systemic Recurrence in Rectal Cancer. Ann. Surg. Oncol.
13: 645-650
[Abstract][Full Text]
Watanabe, T., Komuro, Y., Kiyomatsu, T., Kanazawa, T., Kazama, Y., Tanaka, J., Tanaka, T., Yamamoto, Y., Shirane, M., Muto, T., Nagawa, H.
(2006). Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles.. Cancer Res.
66: 3370-3374
[Abstract][Full Text]
Watanabe, T., Kanazawa, T., Kazama, Y., Tanaka, J., Tanaka, T., Ishihara, S., Nagawa, H.
(2006). SMAD4 Levels and Allelic Imbalance in 18q21 in Colorectal Cancer. Clin. Cancer Res.
12: 1654-1654
[Full Text]
Arango, D., Alhopuro, P., Aaltonen, L. A.
(2006). Reply to the Letter to the Editor by Watanabe et al.. Clin. Cancer Res.
12: 1654-1655
[Full Text]
Watanabe, T., Kanazawa, T., Kazama, Y., Tanaka, J., Tanaka, T., Ishihara, S., Nagawa, H.
(2005). TP53 Mutation and Microsatellite Instability Status for the Prediction of Survival in Adjuvant-Treated Colon Cancer Patients. JCO
23: 9031-9032
[Full Text]
Benatti, P., Gafa, R., Barana, D., Marino, M., Scarselli, A., Pedroni, M., Maestri, I., Guerzoni, L., Roncucci, L., Menigatti, M., Roncari, B., Maffei, S., Rossi, G., Ponti, G., Santini, A., Losi, L., Di Gregorio, C., Oliani, C., Ponz de Leon, M., Lanza, G.
(2005). Microsatellite Instability and Colorectal Cancer Prognosis. Clin. Cancer Res.
11: 8332-8340
[Abstract][Full Text]
Nambiar, P. R., Boutin, S. R., Raja, R., Rosenberg, D. W.
(2005). Global Gene Expression Profiling: A Complement to Conventional Histopathologic Analysis of Neoplasia. Vet Pathol
42: 735-752
[Abstract][Full Text]
Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C.-R., Manova-Todorova, K., Blasberg, R., Gerald, W. L., Massague, J.
(2005). Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA
102: 13909-13914
[Abstract][Full Text]
Alhopuro, P., Alazzouzi, H., Sammalkorpi, H., Davalos, V., Salovaara, R., Hemminki, A., Jarvinen, H., Mecklin, J.-P., Schwartz, S. Jr., Aaltonen, L. A., Arango, D.
(2005). SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer. Clin. Cancer Res.
11: 6311-6316
[Abstract][Full Text]
Westra, J. L., Schaapveld, M., Hollema, H., de Boer, J. P., Kraak, M. M.J., de Jong, D., ter Elst, A., Mulder, N. H., Buys, C. H.C.M., Hofstra, R. M.W., Plukker, J. T.M.
(2005). Determination of TP53 Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer Patients. JCO
23: 5635-5643
[Abstract][Full Text]
Allen, W. L., Johnston, P. G.
(2005). Role of Genomic Markers in Colorectal Cancer Treatment. JCO
23: 4545-4552
[Abstract][Full Text]
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., Koeppen, H.
(2005). Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab. JNCI J Natl Cancer Inst
97: 981-989
[Abstract][Full Text]
Ricciardiello, L., Ceccarelli, C., Angiolini, G., Pariali, M., Chieco, P., Paterini, P., Biasco, G., Martinelli, G. N., Roda, E., Bazzoli, F.
(2005). High Thymidylate Synthase Expression in Colorectal Cancer with Microsatellite Instability: Implications for Chemotherapeutic Strategies. Clin. Cancer Res.
11: 4234-4240
[Abstract][Full Text]
Johnston, P. G.
(2005). Stage II Colorectal Cancer: To Treat or not to Treat. The Oncologist
10: 332-334
[Full Text]
Alazzouzi, H., Alhopuro, P., Salovaara, R., Sammalkorpi, H., Jarvinen, H., Mecklin, J.-P., Hemminki, A., Schwartz, S. Jr., Aaltonen, L. A., Arango, D.
(2005). SMAD4 as a Prognostic Marker in Colorectal Cancer. Clin. Cancer Res.
11: 2606-2611
[Abstract][Full Text]
Kidd, E. A., Yu, J., Li, X., Shannon, W. D., Watson, M. A., McLeod, H. L.
(2005). Variance in the Expression of 5-Fluorouracil Pathway Genes in Colorectal Cancer. Clin. Cancer Res.
11: 2612-2619
[Abstract][Full Text]
Elliott, R. L., Blobe, G. C.
(2005). Role of Transforming Growth Factor Beta in Human Cancer. JCO
23: 2078-2093
[Abstract][Full Text]
Forrester, E., Chytil, A., Bierie, B., Aakre, M., Gorska, A. E., Sharif-Afshar, A.-R., Muller, W. J., Moses, H. L.
(2005). Effect of Conditional Knockout of the Type II TGF-{beta} Receptor Gene in Mammary Epithelia on Mammary Gland Development and Polyomavirus Middle T Antigen Induced Tumor Formation and Metastasis. Cancer Res.
65: 2296-2302
[Abstract][Full Text]
Hatch, S. B., Lightfoot, H. M. Jr., Garwacki, C. P., Moore, D. T., Calvo, B. F., Woosley, J. T., Sciarrotta, J., Funkhouser, W. K., Farber, R. A.
(2005). Microsatellite Instability Testing in Colorectal Carcinoma: Choice of Markers Affects Sensitivity of Detection of Mismatch Repair-Deficient Tumors. Clin. Cancer Res.
11: 2180-2187
[Abstract][Full Text]
Meyers, M., Wagner, M. W., Mazurek, A., Schmutte, C., Fishel, R., Boothman, D. A.
(2005). DNA Mismatch Repair-dependent Response to Fluoropyrimidine-generated Damage. J. Biol. Chem.
280: 5516-5526
[Abstract][Full Text]
Popat, S., Hubner, R., Houlston, R.S.
(2005). Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis. JCO
23: 609-618
[Abstract][Full Text]
Muraoka-Cook, R. S., Dumont, N., Arteaga, C. L.
(2005). Dual Role of Transforming Growth Factor {beta} in Mammary Tumorigenesis and Metastatic Progression. Clin. Cancer Res.
11: 937s-943s
[Abstract][Full Text]
Muraoka-Cook, R. S., Kurokawa, H., Koh, Y., Forbes, J. T., Roebuck, L. R., Barcellos-Hoff, M. H., Moody, S. E., Chodosh, L. A., Arteaga, C. L.
(2004). Conditional Overexpression of Active Transforming Growth Factor {beta}1 In vivo Accelerates Metastases of Transgenic Mammary Tumors. Cancer Res.
64: 9002-9011
[Abstract][Full Text]
Nakamura, M., Miyamoto, S., Maeda, H., Zhang, S.-c., Sangai, T., Ishii, G., Hasebe, T., Endoh, Y., Saito, N., Asaka, M., Ochiai, A.
(2004). Low Levels of Insulin-Like Growth Factor Type 1 Receptor Expression at Cancer Cell Membrane Predict Liver Metastasis in Dukes' C Human Colorectal Cancers. Clin. Cancer Res.
10: 8434-8441
[Abstract][Full Text]
Swallow, C. J., Partridge, E. A., Macmillan, J. C., Tajirian, T., DiGuglielmo, G. M., Hay, K., Szweras, M., Jahnen-Dechent, W., Wrana, J. L., Redston, M., Gallinger, S., Dennis, J. W.
(2004). {alpha}2HS-glycoprotein, an Antagonist of Transforming Growth Factor {beta} In vivo, Inhibits Intestinal Tumor Progression. Cancer Res.
64: 6402-6409
[Abstract][Full Text]
Zaniboni, A., Labianca, R.
(2004). Adjuvant therapy for stage II colon cancer: an elephant in the living room?. Ann Oncol
15: 1310-1318
[Abstract][Full Text]
Geller, J. I., Szekely-Szucs, K., Petak, I., Doyle, B., Houghton, J. A.
(2004). P21Cip1 Is a Critical Mediator of the Cytotoxic Action of Thymidylate Synthase Inhibitors in Colorectal Carcinoma Cells. Cancer Res.
64: 6296-6303
[Abstract][Full Text]
Mehlen, P., Fearon, E. R.
(2004). Role of the Dependence Receptor DCC in Colorectal Cancer Pathogenesis. JCO
22: 3420-3428
[Abstract][Full Text]
Biswas, S., Chytil, A., Washington, K., Romero-Gallo, J., Gorska, A. E., Wirth, P. S., Gautam, S., Moses, H. L., Grady, W. M.
(2004). Transforming Growth Factor {beta} Receptor Type II Inactivation Promotes the Establishment and Progression of Colon Cancer. Cancer Res.
64: 4687-4692
[Abstract][Full Text]
Gill, S., Loprinzi, C. L., Sargent, D. J., Thome, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., Labianca, R., Chen, W., Cha, S. S., Heldebrant, M. P., Goldberg, R. M.
(2004). Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. JCO
22: 1797-1806
[Abstract][Full Text]
Wang, Y., Jatkoe, T., Zhang, Y., Mutch, M. G., Talantov, D., Jiang, J., McLeod, H. L., Atkins, D.
(2004). Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer. JCO
22: 1564-1571
[Abstract][Full Text]
Garrity, M. M., Burgart, L. J., Mahoney, M. R., Windschitl, H. E., Salim, M., Wiesenfeld, M., Krook, J. E., Michalak, J. C., Goldberg, R. M., O'Connell, M. J., Furth, A. F., Sargent, D. J., Murphy, L. M., Hill, E., Riehle, D. L., Meyers, C. H., Witzig, T. E.
(2004). Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer: A North Central Cancer Treatment Group Study. JCO
22: 1572-1582
[Abstract][Full Text]
Parc, Y, Gueroult, S, Mourra, N, Serfaty, L, Flejou, J-F, Tiret, E, Parc, R
(2004). Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut
53: 371-375
[Abstract][Full Text]
Garcia, J M, Rodriguez, R, Dominguez, G, Silva, J M, Provencio, M, Silva, J, Colmenarejo, A, Millan, I, Munoz, C, Salas, C, Coca, S, Espana, P, Bonilla, F
(2003). Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer. Gut
52: 1756-1763
[Abstract][Full Text]
Risques, R.-A., Moreno, V., Ribas, M., Marcuello, E., Capella, G., Peinado, M. A.
(2003). Genetic Pathways and Genome-Wide Determinants of Clinical Outcome in Colorectal Cancer. Cancer Res.
63: 7206-7214
[Abstract][Full Text]
Allegra, C. J., Kim, G., Kirsch, I. R., Iacopetta, B., Elsaleh, H., Zeps, N., Jimenez, J. J., Blanes, A., Diaz-Cano, S. J., Gryfe, R., Ribic, C. M., Sargent, D. J.
(2003). Microsatellite Instability in Colon Cancer. NEJM
349: 1774-1776
[Full Text]
Garcia, J. M., Rodriguez, R., Silva, J., Munoz, C., Dominguez, G., Silva, J. M., Carcereny, E., Provencio, M., Espana, P., Bonilla, F.
(2003). Intratumoral Heterogeneity in Microsatellite Alterations in BRCA1 and PTEN Regions in Sporadic Colorectal Cancer. Ann. Surg. Oncol.
10: 876-881
[Abstract][Full Text]
Rau, B., Sturm, I., Lage, H., Berger, S., Schneider, U., Hauptmann, S., Wust, P., Riess, H., Schlag, P. M., Dorken, B., Daniel, P. T.
(2003). Dynamic Expression Profile of p21WAF1/CIP1 and Ki-67 Predicts Survival in Rectal Carcinoma Treated With Preoperative Radiochemotherapy. JCO
21: 3391-3401
[Abstract][Full Text]
Nash, G.M., Gimbel, M., Shia, J., Culliford, A.T., Nathanson, D.R., Ndubuisi, M., Yamaguchi, Y., Zeng, Z.S., Barany, F., Paty, P.B.
(2003). Automated, Multiplex Assay for High-Frequency Microsatellite Instability in Colorectal Cancer. JCO
21: 3105-3112
[Abstract][Full Text]
Roberts, A. B., Wakefield, L. M.
(2003). The two faces of transforming growth factor {beta} in carcinogenesis. Proc. Natl. Acad. Sci. USA
100: 8621-8623
[Full Text]
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., Tu, D., Redston, M., Gallinger, S.
(2003). Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. NEJM
349: 247-257
[Abstract][Full Text]
Graziano, F., Cascinu, S.
(2003). Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?. Ann Oncol
14: 1026-1038
[Abstract][Full Text]
Diep, C. B., Thorstensen, L., Meling, G. I., Skovlund, E., Rognum, T. O., Lothe, R. A.
(2003). Genetic Tumor Markers With Prognostic Impact in Dukes' Stages B and C Colorectal Cancer Patients. JCO
21: 820-829
[Abstract][Full Text]
Allegra, C., Sargent, D.
(2003). Molecular Diagnostics: Assays, Tissues, Progress, and Pitfalls. JCO
21: 395-396
[Full Text]
Allegra, C. J., Paik, S., Colangelo, L. H., Parr, A. L., Kirsch, I., Kim, G., Klein, P., Johnston, P. G., Wolmark, N., Wieand, H. S.
(2003). Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. JCO
21: 241-250
[Abstract][Full Text]
Koshiji, M., Yonekura, Y., Saito, T., Sakaida, N., Uemura, Y., Yoshioka, K.
(2002). Genetic Alterations in Normal Epithelium of Colorectal Cancer Patients May Be a Useful Indicator for Subsequent Metachronous Tumor Development. Ann. Surg. Oncol.
9: 580-586
[Abstract][Full Text]
Choi, S.-W., Lee, K. J., Bae, Y.-A., Min, K.-O., Kwon, M.-S., Kim, K.-M., Rhyu, M.-G.
(2002). Genetic Classification of Colorectal Cancer Based on Chromosomal Loss and Microsatellite Instability Predicts Survival. Clin. Cancer Res.
8: 2311-2322
[Abstract][Full Text]
Koopmans, P P
(2002). Clinical endpoints in trials of drugs for cancer: time for a rethink?. BMJ
324: 1389-1391
[Full Text]
Duval, A., Hamelin, R.
(2002). Mutations at Coding Repeat Sequences in Mismatch Repair-deficient Human Cancers: Toward a New Concept of Target Genes for Instability. Cancer Res.
62: 2447-2454
[Abstract][Full Text]
Allegra, C.
(2002). Thymidylate Synthase Levels: Prognostic, Predictive, or Both?. JCO
20: 1711-1713
[Full Text]
Allegra, C. J., Parr, A. L., Wold, L. E., Mahoney, M. R., Sargent, D. J., Johnston, P., Klein, P., Behan, K., O'Connell, M. J., Levitt, R., Kugler, J. W., Tria Tirona, M., Goldberg, R. M.
(2002). Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer. JCO
20: 1735-1743
[Abstract][Full Text]
Sloan, J. A., Goldberg, R. M., Sargent, D. J., Vargas-Chanes, D., Nair, S., Cha, S. S., Novotny, P. J., Poon, M. A., O'Connell, M. J., Loprinzi, C. L.
(2002). Women Experience Greater Toxicity With Fluorouracil-Based Chemotherapy for Colorectal Cancer. JCO
20: 1491-1498
[Abstract][Full Text]
Xie, W., Mertens, J. C., Reiss, D. J., Rimm, D. L., Camp, R. L., Haffty, B. G., Reiss, M.
(2002). Alterations of Smad Signaling in Human Breast Carcinoma Are Associated with Poor Outcome: A Tissue Microarray Study. Cancer Res.
62: 497-505
[Abstract][Full Text]
Augenlicht, L. H., Wadler, S., Arango, D.
(2001). Clinical Response to Fluorouracil and p53. NEJM
345: 1065-1066
[Full Text]
(2001). Molecular Predictors of Survival After Colon Cancer Chemotherapy. JWatch Gastroenterology
2001: 7-7
[Full Text]